EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Open Access · CC BY-NC 3.0

Ensifentrine Added on to Dual Bronchodilator or Triple Therapy Demonstrates Clinically Meaningful Improvement in CAT Score in Symptomatic Patients with Chronic Obstructive Pulmonary Disease

Thomas M Siler iD, Tara Rheault, Daniel Reyner iD, Margot MacDonald-Berko iD, John Davidson, Kathleen Rickard iD

International Journal of Chronic Obstructive Pulmonary Disease · 2026

DOI: 10.2147/copd.s589655 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift International Journal of Chronic Obstructive Pulmonary Disease, 2026. Verfasst von Thomas M Siler und 5 weiteren Autor:innen. Beteiligte Einrichtung: Midwest Chest Consultants, PC, Saint Charles, MO, USA. Hauptthemen laut MEDLINE: Adrenergic beta-2 Receptor Agonists, Bronchodilator Agents, Lung, Muscarinic Antagonists. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adrenergic beta-2 Receptor AgonistsBronchodilator AgentsLungMuscarinic AntagonistsPhosphodiesterase 3 InhibitorsPhosphodiesterase 4 InhibitorsPiperidinesPulmonary Disease, Chronic ObstructivePyrimidinonesAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedAdministration, InhalationDrug Therapy, CombinationForced Expiratory VolumeHealth StatusRecovery of FunctionSeverity of Illness IndexTime FactorsTreatment OutcomeIsoquinolines

Stichwörter der Autor:innen

COPD Assessment Testchronic obstructive pulmonary diseaseensifentrinephosphodiesterase inhibitorquality of life

Substanzen

Adrenergic beta-2 Receptor AgonistsBronchodilator AgentsensifentrineMuscarinic AntagonistsPhosphodiesterase 3 InhibitorsPhosphodiesterase 4 InhibitorsPiperidinesPyrimidinonesIsoquinolines

Autor:innen und Institutionen

  • Midwest Chest Consultants, PC, Saint Charles, MO, USA.
  • Verona Pharma, a Subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
  • Stat One LLC, Cary, NC, USA.

ORCID-Profile: Thomas M Siler, Daniel Reyner, Margot MacDonald-Berko, Kathleen Rickard

Zitieren

APA

Siler, T. M., Rheault, T., Reyner, D., MacDonald-Berko, M., Davidson, J., & Rickard, K. (2026). Ensifentrine Added on to Dual Bronchodilator or Triple Therapy Demonstrates Clinically Meaningful Improvement in CAT Score in Symptomatic Patients with Chronic Obstructive Pulmonary Disease. International Journal of Chronic Obstructive Pulmonary Disease. https://doi.org/10.2147/copd.s589655

Vancouver

Siler TM, Rheault T, Reyner D, MacDonald-Berko M, Davidson J, Rickard K. Ensifentrine Added on to Dual Bronchodilator or Triple Therapy Demonstrates Clinically Meaningful Improvement in CAT Score in Symptomatic Patients with Chronic Obstructive Pulmonary Disease. International Journal of Chronic Obstructive Pulmonary Disease. 2026. doi:10.2147/copd.s589655

BibTeX
@article{Siler2026,
  author = {Siler, Thomas M and Rheault, Tara and Reyner, Daniel and MacDonald-Berko, Margot and Davidson, John and Rickard, Kathleen},
  title = {Ensifentrine Added on to Dual Bronchodilator or Triple Therapy Demonstrates Clinically Meaningful Improvement in CAT Score in Symptomatic Patients with Chronic Obstructive Pulmonary Disease},
  journal = {International Journal of Chronic Obstructive Pulmonary Disease},
  year = {2026},
  doi = {10.2147/copd.s589655}
}
Kostenlos starten →